Now in its fifteenth year, the rEVOLUTION Symposium has become the place to discuss the most important strategic problems facing pharma and biotech CSOs. We will examine the organization and management of R&D to uncover new disruptive discovery and development models and assess the continued impact of pricing, reimbursement, regulation and globalization on our industry.
Since thelast rEVOLUTION meeting, a lot has happened across our environment — robust financial markets, passage of health care reform, and continued scrutiny on cost containment. R&D has already begun to change — and that change will become transformational between now and 2020. The 2018 rEVOLUTION meeting thus comes at a pivotal time. Topics developed with our Steering Committee will illuminate new paths, models, and ways of thinking to enhance the industry’s research productivity and economics.
Venatorx's President and CEO, Christopher J. Burns, Ph.D., will participate on a panel entitled, "Panel – Man vs. Microbe," which will take place on April 5, 2018 at 10:30am ET at the St. Regis Hotel in Washington, DC.
About the Panel: In the never-ending battle between man and microbe it appears that microbe is gaining the upper hand. Despite the need for new and effective antimicrobials due to growing resistance, the challenging reimbursement environment, the continued track record of poor commercial launches of new agents and antimicrobial stewardship efforts that reserve new drugs to last line status have collectively resulted in a sparse pipeline of new drugs. This market inefficiency has not gone unnoticed. The assembled panel of infectious disease innovators will first frame the unmet need and key challenges in the space then discuss recent regulatory innovation, novel private public partnerships, various legislative pull incentives, and the latest therapeutic approaches to address the problem of multi-drug resistant pathogens.